Skip to main content

Advertisement

Log in

Fungal Infections and New Biologic Therapies

  • Infections and Arthritis (K Winthrop, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The development of biologic therapies targeting proinflammatory mediators has led to significant advances in the treatment of immune-mediated inflammatory diseases (IMIDs). Blocking undesired inflammatory effects also has the potential to disrupt the body’s immune response and increase the risk for infections, including fungal infections. This review summarizes the published data on the frequency and risk for fungal infections among patients treated with biologics, with a focus on the newer therapies approved for use with IMIDs in the last 10 years. The use of biologics is associated with a small but important risk of fungal infections. Pneumocystis jirovecii pneumonia, histoplasmosis, and candidiasis are some of the most common fungal infections associated with biologics. Providers should be vigilant for fungal infection among patients taking biologics, be aware that biologic agents may alter the typical presentation of fungal infections, and take timely steps to diagnose and treat fungal infection to reduce resultant morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis. 2014;58(11):1587–98. doi:10.1093/cid/ciu104. Good overall review of many of the biologic agents and their mechanism of action, date of approval, and associated infection risk.

    Article  CAS  PubMed  Google Scholar 

  2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93. doi:10.1002/art.10524.

    Article  PubMed  Google Scholar 

  3. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139. doi:10.1186/ar3453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649–57. doi:10.1093/cid/ciu185. Comprehensive analysis of risk of all opportunistic infections, including fungal infections. Particular strength is that this paper included many of the newer biologic agents.

    Article  PubMed  Google Scholar 

  5. Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis. 2014;73(11):1942–8. doi:10.1136/annrheumdis-2013-203407. Analysis of viral an non-viral opportunistic infections among TNF-alpha inhibitor users.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. FDA. 2001. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113512.htm. Accessed Jan 29,2016.

  7. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85. doi:10.1001/jama.295.19.2275.

    Article  CAS  PubMed  Google Scholar 

  8. Ford AC, Peyrin-Biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-[alpha] Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2013;108(8):1268–76. doi:10.1038/ajg.2013.138.

    Article  CAS  PubMed  Google Scholar 

  9. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31. doi:10.1093/rheumatology/keq242.

    Article  CAS  Google Scholar 

  10. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–23. doi:10.1136/ard.2010.137422.

    Article  CAS  PubMed  Google Scholar 

  11. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181–94.

    Article  CAS  PubMed  Google Scholar 

  12. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10):2565–70. doi:10.1002/art.10583.

    Article  CAS  PubMed  Google Scholar 

  13. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50(6):1959–66. doi:10.1002/art.20454.

    Article  CAS  PubMed  Google Scholar 

  14. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis. 2005;41 Suppl 3:S208–12. doi:10.1086/430000.

    Article  CAS  PubMed  Google Scholar 

  15. Salt E, Wiggins AT, Rayens MK, et al. Risk factors for targeted fungal and mycobacterial infections in patients taking TNF-alpha inhibitors. Arthritis Rheum. 2015. doi:10.1002/art.39468. This article assesses risk of fungal infection in TNF-alpha inhibitor users (not limited to IMID patients) and is one of the few studies that focuses specifically on fungal infections in this population.

    Google Scholar 

  16. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96–103. doi:10.1136/annrheumdis-2013-203660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40(8):903–16. doi:10.1111/apt.12930.

    Article  CAS  PubMed  Google Scholar 

  18. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55. doi:10.1136/annrheumdis-2013-203696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Donahue KE, Jonas DE, Hansen RA, et al. AHRQ comparative effectiveness reviews. Drug therapy for rheumatoid arthritis in adults: an update. . 2012.

  20. Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538–46. doi:10.1136/annrheumdis-2013-204195.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95. doi:10.1053/j.gastro.2013.05.048.

    Article  CAS  PubMed  Google Scholar 

  22. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.e1. doi:10.1053/j.gastro.2013.06.010.

    Article  CAS  PubMed  Google Scholar 

  23. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):437–49. doi:10.1093/rheumatology/keq287.

    Article  CAS  Google Scholar 

  24. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32. doi:10.1136/ard.2007.083188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94. doi:10.1136/annrheumdis-2013-203843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lee YH, Bae SC. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2015. doi:10.1111/1756-185x.12822.

    Google Scholar 

  27. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009(1):Cd005121. doi:10.1002/14651858.CD005121.pub3.

  28. Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheum. 2015;67(10):2759–70. doi:10.1002/art.39234.

    Article  Google Scholar 

  29. Kremer JM, Peterfy C, Russell AS, et al. Long term safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol. 2014;41(6):1077–87. doi:10.3899/jrheum.130263.

    Article  CAS  PubMed  Google Scholar 

  30. Alten R, Kaine J, Keystone E, et al. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheum. 2014;66(8):1987–97. doi:10.1002/art.38687.

    Article  CAS  Google Scholar 

  31. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–16. doi:10.1002/art.22070.

    Article  CAS  PubMed  Google Scholar 

  32. van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Long term safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–6. doi:10.3899/jrheum.150051.

    Article  PubMed  Google Scholar 

  33. Greenwald MW, Shergy WJ, Kaine JL, et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011;63(3):622–32. doi:10.1002/art.30194.

    Article  CAS  PubMed  Google Scholar 

  34. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14.

    CAS  PubMed  Google Scholar 

  35. Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54. doi:10.1111/bjd.12214.

    Article  CAS  PubMed  Google Scholar 

  36. Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742–51. doi:10.1016/j.jaad.2011.06.041.

    Article  CAS  PubMed  Google Scholar 

  37. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9. doi:10.1136/annrheumdis-2013-204655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Cantini F, Niccoli L, Nannini C, et al. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. doi:http://dx.doi.org/10.1016/j.semarthrit.2015.10.001.

  39. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–28. doi:10.1056/NEJMoa1203572.

    Article  CAS  PubMed  Google Scholar 

  40. Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–23. doi:10.1136/annrheumdis-2013-204248.

    Article  CAS  PubMed  Google Scholar 

  41. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–62. doi:10.1093/rheumatology/keq343.

    Article  CAS  Google Scholar 

  42. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi:10.1186/ar3455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol. 2012;22(1):122–7. doi:10.1007/s10165-011-0488-6.

    Article  CAS  PubMed  Google Scholar 

  44. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–61. doi:10.7326/0003-4819-159-4-201308200-00006.

    Article  PubMed  Google Scholar 

  45. Winthrop KL, Park S-H, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-207319.

    Google Scholar 

  46. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. doi:10.1056/NEJMoa1215739.

    Article  CAS  PubMed  Google Scholar 

  47. Wang MC, Zhang LY, Han W, et al. PRISMA—efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2014;93(28):e326. doi:10.1097/md.0000000000000326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Dulai PS, Mosli M, Khanna R, et al. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015;35(4):412–23. doi:10.1002/phar.1561.

    Article  CAS  PubMed  Google Scholar 

  49. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. doi:10.1056/NEJMoa1314258.

    Article  PubMed  Google Scholar 

  50. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39. doi:10.1056/NEJMoa1412679.

    Article  CAS  PubMed  Google Scholar 

  51. Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066.

    Article  PubMed  Google Scholar 

  52. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51. doi:10.1016/s0140-6736(15)60125-8.

    Article  CAS  PubMed  Google Scholar 

  53. Genovese MC, Braun DK, Erickson JS, et al. Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase ii study in biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol. 2015. doi:10.3899/jrheum.140831.

    Google Scholar 

  54. Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep. 2014;16(10):445. doi:10.1007/s11926-014-0445-4.

    Article  PubMed  Google Scholar 

  55. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47(10):915–23.

    Article  PubMed  Google Scholar 

  56. Arnold TM, Sears CR, Hage CA. Invasive fungal infections in the era of biologics. Clin Chest Med. 2009;30(2):279–86. doi:10.1016/j.ccm.2009.02.007. vi.

    Article  PubMed  Google Scholar 

  57. Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol. 2009;26(3):175–83. doi:10.1016/j.riam.2009.04.001.

    Article  PubMed  Google Scholar 

  58. Bardazzi F, Balestri R, Rech G, et al. Dermatophytosis during anti-TNF-alpha monoclonal antibody therapy. Mycoses. 2011;54(5):e619–20. doi:10.1111/j.1439-0507.2010.01930.x.

    Article  PubMed  Google Scholar 

  59. Balestri R, Rech G, Piraccini BM, et al. Pityriasis versicolor during anti-TNF-alpha monoclonal antibody therapy: therapeutic considerations. Mycoses. 2012;55(5):444–6. doi:10.1111/j.1439-0507.2012.02170.x.

    Article  CAS  PubMed  Google Scholar 

  60. Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and Other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis. 2008;46(11):1738–40. doi:10.1086/587989.

    Article  PubMed  Google Scholar 

  61. Benedict K, Derado G, Mody R. Histoplasmosis-associated hospitalizations in the United States, 2001–2012 Open Forum Infectious Diseases. 2016 (in press).

  62. Ordonez ME, Farraye FA, Di Palma JA. Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy. Inflamm Bowel Dis. 2013;19(11):2490–500. doi:10.1097/MIB.0b013e31828f1fba.

    Article  PubMed  Google Scholar 

  63. Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85–92. doi:10.1086/648724.

    Article  CAS  PubMed  Google Scholar 

  64. Olson TC, Bongartz T, Crowson CS, et al. Histoplasmosis infection in patients with rheumatoid arthritis, 1998–2009. BMC Infect Dis. 2011;11:145. doi:10.1186/1471-2334-11-145.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Taroumian S, Knowles SL, Lisse JR, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res. 2012;64(12):1903–9. doi:10.1002/acr.21784.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Snigdha Vallabhaneni.

Ethics declarations

Conflict of Interest

SV and TC declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Additional information

This article is part of the Topical Collection on Infections and Arthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vallabhaneni, S., Chiller, T.M. Fungal Infections and New Biologic Therapies. Curr Rheumatol Rep 18, 29 (2016). https://doi.org/10.1007/s11926-016-0572-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0572-1

Keywords

Navigation